<DOC>
	<DOCNO>NCT00505232</DOCNO>
	<brief_summary>Mantle Cell Lymphoma ( MCL ) malignancy poor response treatment median survival 2- 4 year since diagnosis . Although histology similar indolent lymphoma , MCL currently consider aggressive tumour . Few prospective therapeutic trial report MCL , result difficult interpret due treatment heterogeneity . It known standard chemotherapy clinically aggressive lymphoma yield poor result . Recently , good result communicate intense induction chemotherapy treatment consolidate response high dose chemotherapy stem cell support . Keeping mind consideration , use intensive induction treatment Hyper-CVAD/MTX-AraC associate anti-CD20 order increase overall response rate follow consolidation treatment Ibritumomab -tiuxetan ( Zevalin ) aim eradicate minimal residual disease , responsible relapse .</brief_summary>
	<brief_title>Safety Study Evaluate Induction Consolidation Treatment Patients With Mantle Cell Lymphoma ( LCM-04-02 )</brief_title>
	<detailed_description>Study Design : - The Patients receive 6 cycle induction chemotherapy follow : Anti-CD20/Hyper -CVAD chemotherapy alternate anti-CD20 +MTX/Ara-C chemotherapy . After 4 cycle ( 2 x2 ) , response evaluate . If response ( complete partial ) observe , 2 additional cycle administrate . If less partial response observe , patient study . - Consolidation treatment single dose Y90Ibritumomab -Tiuxetan ( Zevalin ) administer 12 week completion induction chemotherapy . The initial dose Zevalin 0.3 mCi/kg , escalate 0.4 mCi/Kg unacceptable toxicity occur .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All histologic MCL subtypes ( WHO classification ) Age 18 70 year old Performance status 0 2 ( ECOG ) Cardiac ejection fraction &gt; 50 % Adequate organ ( hepatic , cardiac renal ) marrow function : Hb &gt; 10g/dl , neutrophil count &gt; 1500/ µl , platelet &gt; 100000/ µl . Creatinine &lt; 2,5xULN , bilirubin , AST ALT &lt; 2,5xULN . For Y90ibritumomab tiuxetan administration : Bone Marrow Infiltration lymphoma cell &lt; 25 % ; platelet count &gt; 100,000/µl neutrophil count &gt; 1500/µl Informed consent obtain Ann Arbor stage I II without B symptom bulky disease ( &gt; 10 cm ) . Previous chemotherapy radiotherapy treatment . Uncontrolled current illness : Hepatic , renal , cardiovascular , neurological metabolic illness . Symptomatic congestive heart failure , unstable angina pectoris , clinically significant cardiac arrhythmia . HIV , HBV HCV positive serology . Limitation patient´s ability comply treatment followup protocol . Men woman reproductive potential use effective contraceptive method least 12 month end study Acute chronic active infection . Known hypersensitivity drug related compound No informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Y-90 Ibritumomab tiuxetan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Hyper-CVAD</keyword>
	<keyword>Mantle Cell Lymphoma Patients</keyword>
	<keyword>Zevalin ( R )</keyword>
</DOC>